

CITRASATE®

HIGH-FLUX HEMODIALYSIS AND ONLINE HEMODIAFILTRATON WITH CITRASATE





Index

What is Citrasate?	3
What are the side effects of acetate in dialysis and what are the benefits offered by Citrasate?	3
Possible indications for dialysis with Citrasate	4
What is the mechanism of Citrasate inside the dialyzer?	5
Clinical studies with Citrasate	6
High-flux hemodialysis (HD)	6
Online hemodiafiltration (HDF)	
Citrasate can be used on every standard dialysis machine	
Results of the <i>in vitro</i> measurements	
Advantages of using Citrasate	20
Literature	21
Comparison of the composition of ready-to-use citric acid dialysis solution versus acetic acid	23

K [*] 2,00 most Ca ²	on / Composition	1.00	3.8	Le
Natrii chiaridum	263.00 pf	14	4.514,00	menal
Kull chloridum	6,71 pl	K*	90,00	ment
Magnesi eMoridum + 6H,0	4,57 p1	1027	22,00	mend
Culcil chloridum + 2H ₂ D	8,27 g/l	0.0	66,00	mmod
Acutum citricum	6,02 pl 1,84 pl	34.68		mmol
Nutri ecetata × 3H ₂ O	45.00 01	0.00	4.747.00	-
Olycosum anhydricum Albus purificate ed 1000 ml	and be	Glucos		mmid
and the state of t	photokalantipa Galo	utrang 11 same	a furnestor hp 401	42,3351
do num (here puttons = 1.77515	MHOD, LAS. 8.4 % HOD	Stational Radian	the option do not	tergent .
Loss bidden a Dakk or di prosent alle Franzentien all the mody is une disk	and public a line of the	percenter lager MC1	- 10 2051 water (Re	a purficient
OT - LITERACE, M. LPLOTE	about ship	to a the restricted		a av talloan
OT - LTERACE - SALATE				
	town makes at a made in the	-	whether inscission of	-134 481
Composition for in solution poor the	Aper petite di l'amptori l'an	mitange d 11de		ante MEL-
fr composition in to solution provide 41.325147 source quality appropriate togetherate parents' observes if to	Anne pellin di l'ampire l'in In - 1,775 i die in sciuli In adallere provi for year	mitango d' 1144 n de literarlanatie i prito 11 congles p	charac parameter a to and an ALPS in contrast in parameter	ade HEL- artsuite B stans a
fr composition de la solution pour des 61.2251 et sus de qualité agement locarisantes pennett alemént d'un descrisées pelantités à d'armen	Ann pelle à l'ample i la la - 1,775 i de la setada na salation pice de co	milange of 11.00 print all complete prints all complete p	to and an a EUPs in a	ada Mil-
Composition to in adultion provide for 61,2251-07 see to qualitit expression to particular partners' interestion if to descentiging partners' interestion of demons- tion and partners' interestion of demons- partners' interesting on its partners' interesting and and and and and and and and and and	Anno politic di l'angolari i la da - 1, 275 i da la constitu- na adalativa politicaria (1.16) adalativa espinantari (1.16) adalativa fi di la constitu	milange of 11.00 print all complete prints all complete p	to and an a EUPs in a	ade ALL- adaptive in adaptive in
Comparation to including peer file Comparation to including peer file Comparation of the solution	Aper patter d'i sergini i te la - 1,775 (de la solution en adalates provider de ren educates quincares (i la serang 1, 6%, d'incentes analysis i serand / la	mitango d' 1140 n da bisarbondi pilita 11 milita (ji ganana da bisarbondi) natanita (ji ganta	and an U.E.P. in resident U.E.P. in resident in C.P. in resident in C. 2015 No. 1 resident in C. 2015 No. 1	ada HL- adaa A da Gasa ada Gasa ada Gasa
Comparison in its total in port for 41,2214 of one-to-quality sympho- tic statement particle in the sympho- tic statement particle of demands constrained particle of demands of portunity - 1,275 to SarrOl, with the symphotic demands of the statement of the symphotic statement of the symphotic default of the law monitories of the symphotic state of the symphotic default of the symphotic constraints of the symphotic statement of the symphotic statement of the symphotic constraints of the symphotic statement of the symphotic statement of the symphotic constraints of the symphotic statement of the symphotic statement of the symphotic statement of the symphotic statement of the symphotic statement of the symphotic statement of the symphotic statement of the symphotic stat	Appendix of a series to a + 2,775 (a) is a statistic as addition plan for an addition plan for a statistic addition a series / 10 addition as an and / 10 addition as a series / 10 addition as a statistican (1) addition addition (1) addition addition (1) addition addition (1) addition addition (1) addition (1)	mitango d' 1140 n da bisarbondi pilita 11 milita (ji ganana da bisarbondi) natanita (ji ganta	and an U.E.P. in resident U.E.P. in resident in C.P. in resident in C. 2015 No. 1 resident in C. 2015 No. 1	ada HL- adaa A da Gasa ada Gasa ada Gasa
Fir Comparison to its solution poor the 41.2251 of some the quarter description back-bandle parameter (description to description planameter of description to performant), 21755 is SancOlo, sp and the approximation of the solution is an owner of the approximation is an owner of the approximation of the annual spectrum of the solution of the solution of the approximation of the isome solution of the solution of the solution of the approximation of the solution of the approximation of the solution of the so	Appendix a l'angle l'a la 1,773 de la content e databas pinteres (l'à mang d. 25 d'angles mang d. 25 d'angles mang de la content la	mitange d' 1140 n de lanachender pélo: 11 ongén p agencies de la lig ad carbijo godin A lancentei fige i	111 - Q.255 to 1	ante HL- articulte B atom Anas atom Anas Anas Anas Anas Anas Anas Anas Anas
Comparation for its solution proof the first sci.2251-of one is southin somewise transformation protection and the southern protection of the south production of the southern of the southern of the southern of the formation of the southern of the southern one of the south of the southern of the southern one of the south of the southern of the southern one of the south of the southern of the southern one of the south of the southern of the southern one of the south of the southern of the southern of the southern one of the south of the southern of the southern of the south of the southern of the	Appar paties 47 comptex 1 or a + 32/75 to the terrorism and addition proceeding on the patient operations of the metalog of the Advancement and the terrorism of the patient bioactions of the metalog of the Advancement o	mitage (* 114) a la factoria (* 1 pilo 21 million) an antige golf (* al antige golf (* 4 factoria (* 1)) a (* 1), malient antige golf (* 1)	(1) Construction (Construction) (Construction) (Construction) (Construction) (Construction) (Construction) (Construction) (Construction) (Construction) (Construction) (Construction) (Construction) (Construction) (Construction) (Construction) (Construction) (Construction) (ante HL- articulte di minere di ante diqua (diqua articulte particulte
Comparison to its challen pare die für 4220147 auss in public angewählt für auchange angewählt die einer die descalation gesterzt in dereit einer die auflichtigt - 12716 5. Merich, die auflichtigt - 12716 5. Merich, Bier auflichtigt - 22716 5. Merich, Bier manufahr wert Bignach die einigen Statistigtigt - 21716 5. Merich, Bier manufahr wert Bignach die einigen Statistigtigt - Bisgehand beitrigt Statistigtigt - Bisgehand beitrigt Statistigtigt - Bisgehand beitrigt	Appen paties 47 compton 1 or a + 32/75 1 de las constitues en autoritaine parte d'arcyan d'archana agrinourang 1 de managér de la constitue d'archana antalisés as constitue d'archana antalisés archana d'archana antalisés archana antalisés arch	mitage (* 114) a la factoria (* 1 pilo 21 million) an antige golf (* al antige golf (* 4 factoria (* 1)) a (* 1), malient antige golf (* 1)	(1) Construction (Construction) (Construction) (Construction) (Construction) (Construction) (Construction) (Construction) (Construction) (Construction) (Construction) (Construction) (Construction) (Construction) (Construction) (Construction) (Construction) (Construction) (ante Hil- artende B aten Anga Anga Anga a Tan At
Fr Comparation for its solution poor the fr clutter of the solution power that beautionappearant measures of the solution polarization is determine polarization of the solution of the polarization of the solution of the polarization of the solution of the formation of the solution of the formation of the solution of	Appen paties 47 compton 1 or a + 32/75 1 de las constitues en autoritaine parte d'arcyan d'archana agrinourang 1 de managér de la constitue d'archana antalisés as constitue d'archana antalisés archana d'archana antalisés archana antalisés arch	mitage (* 114) a la factoria (* 1 pilo 21 million) an antige golf (* al antige golf (* 4 factoria (* 1)) a (* 1), malient antige golf (* 1)	(1) Construction (Construction) (Construction) (Construction) (Construction) (Construction) (Construction) (Construction) (Construction) (Construction) (Construction) (Construction) (Construction) (Construction) (Construction) (Construction) (Construction) (Construction) (ante Hil- artende B aten Anga Anga Anga a Tan At
Comparison to its shadow pare the first 4.223 of the set of public damaged machinest entropy of the same of the set of the set of the same of the set of the set of the set of the public of the set of the set of the public of the set of the se	Appa pella 41 annali 12 da - 2,175 da la sunti na abalias pro diversi darjas ginesing 1 de sanda 8 de 20 de sensati da de sensativa 1 de las de la desensativa de la de sensativa 1 de sensativa 1 de sensativa antipiones persona 6 de julio de	mitage (* 114) a la factoria (* 1 pilo 21 million) an antige golf (* al antige golf (* 4 factoria (* 1)) a (* 1), malient antige golf (* 1)	And a second sec	ante Mil- antesatore deservitore internet internet internet antifactore talgente
Compatible to its validite upon the for acceptance on the validite appears the standard production of dimension discussioning compatibility of the standard compatibility of the standard production the standard is a compatibility of the the standard is a compatibility of the the standard is a compatibility of the standard is a compatibility of the standar	Appen public 47 seruptic 124 dans 1, 2775 1 pit is seruptic seruptic processing 1, 196 seruptic processing 1, 196 seruptic to seruptic 176 seruptic 176 serupt	entering of 11 M is to the content of price all employed and control on price and contrelation and control on price and control	And a second sec	ante Mil- ante ante deservitorio internet intere
Compatible to the shall be proof the the standard account of the shall be than taking account of the shall be than taking account of the shall be than taking account of the shall be and taking - 1278 be than the the shall be the shall be the shall be the shall b	Appendie 21 angeho 12 ange	entempo d' 11 M e de terractionate i peter a l'employent aux control trac e d. C. C. enablement control trace 401 - ens es tracgiotes el Cl - CD -	Address generation of the anti- end of the anti-anti-10 (2015) for a second rate for anti-anti- pa (01) - (2) (2016) for a second rate of the anti- second rate of the an	
Fr c129117 seeks while apendia for c129117 seeks while control control seeks approximate in the seeks of the seeks approximate in the seeks of the set of a regional information of a regional information of a regional information of a regional information information of a regional information of a regional information information of a regional informati	Appen palles 21 annuels 1 an des x 2,275 (de la celeta es adulates pare director anderes galences (1 de annuels) (1 de annuels) (1 de la celeta annuels) (1 de la celeta annuels) (1 de la celeta annuels) (1 de la celeta annuels) annuels) annuels) annuels) annuels)	entango 2 114 n de teuritorito pete al respirar an constructivo de control topo de control de control topo de	oblass possible a to called BLPS to con- served to called a second by possible and the second by the	
Comparison to include a period of restances and a period of the second distances of the second distances of the second dis	Appendie 11 angelie 12 angelie 13 angelie 14 angelie 12 angelie 14	entempo d' 11 M e de terractionate i peter a l'employent aux control trac e d. C. C. enablement control trace 401 - ens es tracgiotes el Cl - CD -	of the advance proceeding of the advance bits proceeding of the advance bits proceeding of the second bits proceeding of the second bits of the second of the second bits of the second of the second bits of the second of the second bits of th	
Fr classifier in white per fat for classifier out with experiment in the second second second second in the second	Anna patter 41 emplei - 14 emplei - 14 emplei - 14 emplei - 15 emplei - 15 emplei - 15 emplei - 16 emp	entango 2 114 n de teuritorito pete al respirar an constructivo de control topo de control de control topo de	of the united is a second to be united to be	
Fr c129117 seeks while apendia for c129117 seeks while control control seeks approximate in the seeks of the seeks approximate in the seeks of the set of a regional information of a regional information of a regional information of a regional information information of a regional information of a regional information information of a regional informati	Anna patter 41 emplei - 14 emplei - 14 emplei - 14 emplei - 15 emplei - 15 emplei - 15 emplei - 16 emp	entango 2 114 n de teuritorito pete al respirar an constructivo de control topo de control top	olden positiv o to allow BLPS to all of the second bill of the positive of the second bill of the second bill of the second bill of	

What is Citrasate[®]?

Citrasate is an innovative formula of acid concentrate for dialysis that contains 0.8 mmol of citric acid and 0.3 mmol/l of acetate, instead of the traditional 3 mmol/l of acetate contained in standard acid concentrates.

The use of an acidifying agent in acid concentrates for dialysis is necessary in order to reach a neutral pH well tolerated by the body and to prevent the precipitation of calcium and magnesium carbonate.

What are the side effects of acetate in dialysis and what are the benefits offered by Citrasate?

With the introduction of the bicarbonate dialysis, the concentration of acetate (or acetic acid) was reduced to 3 mmol/l. However, during the dialysis treatment, acetate ions can cause a series of undesired physiological side effects because of their metabolism to carbon dioxide under consumption of oxygen. The possible side effects of acetate during dialysis are summarized in Table 1.

Physiological effects of acetate during its metabolism	Possible symptoms during and after treatment
Vasodilatation	Hypotension Arrhythmia
Increased need of O ₂	Hypoxemia
Unphysiological formation of intermediate products of metabolism (e.g. aldehydes)	Headache Nausea
Cytokine induction (IL-1) in monocytes	Stimulation of long-term side effects of dialysis treatment (e.g. atherosclerosis and microinflammation)

Table 1: Possible side effects of acetate in dialysis ¹⁻³

The innovative acid concentrate, Citrasate, is partly acidified with citric acid, which generates citrate ions. Citrate ions possess anticoagulant properties because of their complex formation with calcium and magnesium ions. The extent of this anticoagulation is dependent on the concentration of citrate.

To achieve an effective dialysis treatment, it is necessary to prevent blood coagulation in the extracorporeal circuit by using anticoagulation, for which unfractionated heparin is generally administered.

The repeated use of heparin, however, can cause several undesirable side effects. Therefore, if possible, the heparin dose used should be minimized. In the critical case of heparin-induced thrombocytopenia (HIT II), heparin must be avoided entirely. The possible side effects of unfractionated heparin are summarized in Table 2.

Possible side effects of unfractionated heparin	
Increased risk of bleeding	
Partial blockage of the lipid metabolism	
Osteoporosis	
Pruritus	
Heparin-induced release of myeloperoxidase (MPO) from atherosclerotic vessels	
Heparin-induced thrombocytopenia (HIT II)	

Table 2: Possible side effects of unfractionated heparin in dialysis (4-8)


Because the concentration of citrate is very small Citrasate dialysate, if it is used for high-flux hemodialysis (HD), it is not necessary to evaluate the concentration of free calcium ions in the blood or to administer calcium to the blood behind the dialyzer. For the metabolism of citrate through the organism, oxygen is not necessary. In comparison to acetate, citrates half-life is much shorter.

Possible indications for dialysis with Citrasate

On the basis of experience and clinical studies, Citrasate is suited for the following patients while performing different treatment modes of blood purification:

- Pre- or post-operative patients
- Patients with cholesterol embolism
- Patients with gastrointestinal lesions
- Patients with hemorrhagic retinopathies because of diabetes
- Patients with heparin-induced side effects (e.g. pruritus or osteoporosis)
- Patients with acetate-induced side effects

What is the mechanism of Citrasate inside the dialyzer?



STEP 1

In his packaging and at pH 1.9 of citrasate, calcium and citrate ions do not form a complex. The formation of the calcium-citrate (Ca-citrate) complex takes place during the mixing of acid and bicarbonate components inside the dialysis machine, producing the final dialysis fluid.

- Because of the concentration gradients in the dialyzer, free citrate ions diffuse into the blood and bind free calcium ions to form a Ca-citrate complex.
- At the same time, free calcium ions diffuse from the blood to the dialysate side because the ionized calcium has been reduced due to the Ca-citrate complex formation.

Both transport processes lead to a reduction in the concentration of free calcium ions in the blood that is located in the dialyzer therefore cause a local anticoagulatory effect inside the dialyzer.

STEP 2

The Ca-citrate complex entering the blood circuit dissociates into free Ca²⁺ and citrate ions, resulting in free calcium ions again becoming available in the blood in the dialyzer. The citrate ions are metabolized to bicarbonate in the Krebs-cycle. as the dosage of citrate is very low in comparison to regional citrate anticoagulation and the muscle cells can also metabolize citrate can be metabolized by muscle cells, Citrasate can also be used for patients with liver insufficiency.




Fig. 2: Removal of calcium-citrate-complex in the blood and organism

Clinical studies with Citrasate

High-flux hemodialysis (HD)

Reduction in heparin dose which was associated with shorter bleeding time

Kossmann et al. (9) switched 31 patients from normal dialysate containing acetate (NCD) to Citrasate and gradually reduced the heparin dosage. Even with the reduction of heparin by 55%, all the treatments with Citrasate successfully completed without clotting problems.

PATIENTS AND METHODS

31 chronic patients were identified as having post-dialysis bleeding times >15 minutes.

Months 1-2: standard heparin dose


Months 3-4: heparin dose lowered by 33%

Months 5-6: heparin dose lowered by another 33%

Thus, heparin dose was reduced by 55% from their initial dose.

There was no other change in treatment parameters (e.g. session duration, blood flow, dialysate flow, choice of dialyzer).

The bleeding time was measured and the dialysis dose was registered as Kt/V (urea).



Reduction in heparin dose

Ahrenholz and Winkler¹⁰ switched 7 patients from a standard dialysis fluid containing acetate to Citrasate and gradually reduced the heparin dose. Despite the heparin reduction by 50%, all the treatments with Citrasate were successfully finished without clotting problems.



Weeks 3-6: changed standard dialysate to Citrasate; no change in heparin


PATIENTS AND METHODS

7 patients treated with a high-flux dialyzer

Weeks 7-10: dialysis with Citrasate and reduction of heparin in the bolus by 50%

Weeks 11-14: dialysis with Citrasate, bolus of heparin remains at 50%, and reduction of heparin in the continuous dosage by 50%, resulting in a total reduction of 50%

There was no other change in treatment parameters (e.g. session duration, blood flow, dialysate flow, choice of dialyzer).



The results in Fig. 5 show that no significant drop in the dialysis dose or in other clearance values (e.g. phosphate in Fig. 6) takes place despite the reduction of heparin by 50%. In the switch from dialysis fluid containing acetate to Citrasate, without a change in heparin dosage, no increase of dialysis dose (spKt/V) was found in comparison to Kossmann et al.¹¹

Recently, Sands et al.²⁶ confirmed the possibility of a heparin reduction between 20-30% in a prospective multi-center trial. In 92% of 277 dialysis patients, it was found that the dialysis treatment could finish without significant change of urea clearance or adverse events, such as clotting or bleeding.

Increase in dialysis dose and removal of Beta-2 Microglobulin

Kossmann et al.¹¹ switched 142 patients from standard dialysis fluid containing acetate (NCD) to Citrasate and measured the dialysis dose and pre-dialytic Beta-2 Microglobulin (β2M) concentration in the plasma every month, over a period of 6 months.

A significant increase of Kt/V (Fig. 7) and reduction of pre-dialytic β2M plasma levels were observed (Fig. 8).

PATIENTS AND METHODS

142 patients were observed for 6 months

- Follow-up of pre-dialytic β2M values
- Monthly follow-up of Kt/V values

There was no other change in treatment parameters (e.g. session duration, blood flow, dialysate flow, choice of dialyzer).



Dialysis dose and calcium-bicarbonate concentration in plasma

Svara et al.¹² switched five patients from standard dialysis fluid containing acetate (AA) to Citrasate (CA) and measured the urea reduction rate and free calcium, total calcium, and bicarbonate in the plasma at the end of every treatment. A significant increase of 7% in spKt/V was observed (Fig. 9), whereas the other parameters did not change significantly (Fig. 10).

PATIENTS AND METHODS

5 patients observed for 4 weeks

- Calculation of spKt/V values
- Measurement of the pre-dialytic Ca2+, total Ca, and bicarbonate concentration in the plasma

There was no other change in treatment parameters (e.g. session duration, blood flow, dialysate flow, choice of dialyzer).







Fig. 9: Increase in spKt/V

Fig. 10: Timeline of Ca2+ and total Ca in the plasma of one patient


Improvement in hemodynamic stability

From Gabutti et al.,¹³ 25 patients were investigated. Each underwent a total of 375 dialysis sessions either with a standard acetate dialysate (A), a citrate-containing dialysate with (C+), and a citrate-containing



dialysate without (C) calcium supplementation (0.25 mmol/l) adhering to the following study design:

In hypertensive patients, the citrate dialysis resulted in a significantly lower systolic blood pressure (Fig. 11) and an increase in stroke volume (Fig. 12).



Reduction in thrombus formation in the dialyzer using citrate

Citrate versus heparin after 4 hours of hemodialysis




Fig. 13: Polysulfone membrane with low molecular weight heparin¹⁴




Fig. 14: Polysulfone membrane with regional citrate anticoagulation¹⁴



Fig. 15: Dialyzer after rinse back, following 4 hours of hemodialysis with dialysate containing acetate¹⁵



Fig. 16: Dialyzer after rinse back, following 4 hours of hemodialysis with Citrasate¹⁵

Positive impact of Citrasate on coagulation parameters

Since a very low concentration of citrate is contained in Citrasate, its anticoagulatory effect can only develop in the dialyzer during dialysis (i.e. no systemic anticoagulation is to be expected).

Gabutti et al.¹³ measured no significant changes in the formation of the TAT-complex and the F1 and F2 prothrombin fragments (pre- and post-dialytic) in 25 patients and 375 treatments when there was a switch from acetate containing dialysate to one containing citrate. Leimbach et al.¹⁶ made the same observation for the pre- and post-dialytic activated clotting time (ACT) values in 7 patients. Ahrenholz et al.¹⁰ confirmed these findings. In this context, they were also able to show that the ACT dropped even if heparin was




Fig. 17. Time dependence of activated clotting time (ACT) as a function of heparin reduction during dialysis treatment with acetate dialysate versus Citrasate

reduced by 50%, and no clotting events occurred in the dialyzer and in the extracorporeal circuit.

Positive influence of Citrasate on biocompatibility

Myeloperoxidase (MPO) is considered a marker of oxidative stress and a parameter of inflammation in patients⁶ suffering from kidney disease or for patients to be treated with extracorporeal blood purification.¹⁷

MPO can induce vascular complications with several different mechanisms:

- Inhibition of NO-dependent vasorelaxation
- Production of endogenous NO-inhibitors
- Oxidation of LDL with consecutive increased reception in local macrophages
- Production of reactive species

The plasma levels of MPO are associated with atherosclerotic complications and mortality of patients with acute renal failure.¹⁷

Heparin was shown to stimulate the release of MPO from atherosclerotic vessels and to stimulate the activation of leucocytes,¹⁸ independently of any stimulation by the dialyzer.¹⁹ Using unfractionated or low

molecular weight heparin for anticoagulation, MPO and platelet factor 4 will be released immediately after starting dialysis treatment.²⁰ However, using citrate for regional anticoagulation, the release of MPO could be inhibited entirely.²⁰ By means of regional citrate anticoagulation for critical ill acute patients, a significant decrease of mortality was observed²¹ using central veno-venous hemodialysis (CVVH) as the treatment mode. A better recovery of kidney function is supposed as reason.

Ahrenholz and Winkler¹⁰ examined the MPO plasma levels and the leucocyte numbers pre-and postdialytic, as well as 15 minutes after the beginning of the dialysis session, in accordance to the following study protocol:

PATIENTS AND METHODS

8 patients were treated with high-flux dialysis

Weeks 1-2: standard dialysate and previous amount of heparin (bolus + continuously) as baseline treatment

Weeks 3-6: changed standard dialysate to Citrasate; no change in heparin


Weeks 7-10: dialysis with Citrasate and reduction of heparin in the bolus by 50%


Weeks 11-14: dialysis with Citrasate, bolus of heparin remains at 50%, and reduction of heparin in the continuous dosage by 50%, resulting in a total reduction of 50%


There was no other change in treatment parameters (e.g. session duration, blood flow, dialysate flow, choice of dialyzer).


Fig. 18 shows that no significant changes in leucocyte numbers were observed regardless of the amount of dialysate or heparin used. 15 minutes after the start of the dialysis session, however, a significantly lower induction of MPO plasma levels could be observed between acetate-containing dialysate and Citrasate dialysate with the reduced amount of heparin (Fig. 19).

These results can be considered as the first proof that dialysis with Citrasate appears to be more biocompatible for chronic dialysis patients because the reduction of acetate and heparin concentration in dialysate diminishes the inflammatory and oxidative potential in the blood. The question whether the mortality of chronic dialysis patients can be reduced by Citrasate dialysis remains reserved for long-term investigations with a larger patient population.









The successful application of Citrasate for the heparin-free "slow efficiency" dialysis (SLED) for acute treatment of critically ill patients with multiorgan failure or advanced liver failure was described by Ahmad and Tu.²⁴

🗢 Canister

Citrasate Acid Concentrate for Bicarbonate Dialysis K2,00 Ca 1,50 Gluc 1,00 11 460 + 42 2251 H 20 ISO 23500-3

	11 400 + 1.775 NaHCO 38,4%					
11 460 Natrii chloridum Kalii chloridum Galcii chloridum x 840 Acidum citricum Natrii acetats x 34,0 Glycosum anhydricum	263,00 9 6,71 9 9,92 9 6,92 9 1,84 9 45,00 9 ad 1000 =	I Na I K 2. I Ga I Citrate ⁷ I CH ₃ COO I HCO ₃ AI CI	139,75 2,00 0,50 1,50 0,80 0,30 37,04 106,00	mmoli mmoli mmoli mmoli mmoli mmoli mmoli gji		

Conductivity (ready to use soc) 14,91 marcen on concentrat (a, konzentrat) de: Saures Konzentrat (A-Konzentrat) für die Bicarbonal-Hamodialyse (Hinweis en Übermischung mit Bicarbonat (B-Konzentrat) ist zu vermeden**en**. Acid concentrate (A-concentrate) for bicarbonat haemodialysis (Note: over mixing with bicarbonate col contrate (B concentrate) should be avoided) fr: le concentre de dialyse acide (concentre A) pour l'hémodialyse au bicarbonate (note: il faut eviter de trop melanger (concentre A) pour l'hémodialyse (concentre B), sv: Surt dialyskoncentrat (A-koncen-(concentre A) pour l'hémodialyse au bicarbonate (note : il faut éviter de trop melang avec le concentré de bicarbonate (concentre B) sv: Suit dialyskoncentrat (A-koncen-trat) foi bikarbonat-hemodialys (OBS: en överblandning med bikarbonat-koncentrat (B-koncentrat) méter unterliker), der soneheidet diabrakencentrat (A-koncentrat) trat) för omarbonat-nemodiarys (OBS: en overblandning med bikarbonat-koncentrat (B-koncentrat) mäste undvikas). da: syreholdigt dialysekoncentrat (A-koncentrat) (B-koncentrat) máste undvikas). da: syreholdigt dialysekoncentrat (A-koncentrat) bibitarbonat-hæmodialyse (Bernærik: En for høj blanding med bikarbonat-koncentrat) (B-koncentrat) skal undgås). no: surt dialysekonsentrat (A-konsentrat) for bikarbon hemodialyse (hervisning: en blanding med bikarbonat-konsentrat (B-konsentrat) med ungds) ft: Rugstinis dializes koncentratas (.A* konsentrats), skirtas bikarbonat hemodializei (hurodymas: reika vengti masiym su bikarbonato koncentrat (.B* koncentratu)). Iv: Lietosianai gatava bikarbonata hemodializes skoduma sastur in noradits uz attecigas A-komponentes etiketes. Izmanto tika un tuti pec asskadusa

LO Koncentratu// IV. Lietosanar gatava ustarionasa minoosaices saounis saou ir noradits uz atliecigas A-komponentes etiketes Izmanto tikai un tulit poc atlikaidisa

LOT xxxxxxxxxx

53 9999/99

nas ar dejonizetu udeni un piemerota skabes komponenta pie MTN Neubrandenburg GmbH , Gustav Kirchhoff Str. 2 17033 Neubrandenburg: Germany

REF 46000050011

i

5°C / 30°C

CE 2797

460 45

5Le





Online hemodiafiltration (HDF)

The results presented so far relate exclusively to high-flux hemodialysis with Citrasate. The following chapters relate to online hemodiafiltration in both pre- and post-dilution.


The first extensive investigation applying Citrasate in HDF was performed by Ahrenholz et al.²⁷ and Winkler et al.²⁸ with 8 patients. Since the substitution fluid for online HDF is prepared directly from the dialysate, the use of Citrasate means the infusion of a considerable amount of citrate directly into the blood will occur.

During online HDF in pre-dilution mode, the substitution fluid will be infused into the blood before the dialyzer, which means citrate will be included in the mass transfer processes of the dialyzer. During online HDF in post-dilution mode, the infusion of citrate containing fluid takes place after the dialyzer and into the peripheral blood of the patient. Since the effects of Citrasate on free calcium ion concentration and coagulation system cannot be precisely predicted, Citrasate was first applied in the pre-dilution mode of online HDF.

The level of calcium and phosphate in plasma

Because of the previous high-flux dialysis studies¹⁰ with 1.25 mmol/l calcium in the Citrasate dialysate, the calcium concentration was increased to 1.50 mmol/l. The post-treatment values of Ca2+ level out at 1.09 mmol/l for HD and HDF pre-dilution with Citrasate, as shown in Fig. 23. The same value was also achieved for HDF pre-dilution with standard dialysate with 1.25 mmol/l Ca2+. The values for the total calcium amounts are shown in Fig. 24.

Patients usually treated with standard concentrate with 1.25 mmol/l Ca2+ should receive 1.50 mmol/l Ca2+ after changing to Citrasate. This increase becomes necessary to compensate for the iCa-losses resulting from the calcium-citrate complex formation.




Ca2+ concentrations pre- and post-treatment for different treatment modes with and without Citrasate Fig. 24: Total Ca pre- and post-treatment; n=8 Total Ca concentrations pre- and post-treatment for different treatment modes with and without Citrasate


The balance between changes of total Ca and ionized Ca (iCa) during treatments can be expressed as the Ca-GAP, according to the following equation from Gabutti el al. (13, 29):

Ca-GAP = (totalCa post - totalCa pre) - (iCa post - iCa pre)


If the metabolization of citrate is quick, the Ca-GAP becomes smaller than 0,2 (13, 29). As the results in Fig. 25 show, on average this condition was fulfilled.



The calcium-phosphate balance is determined largely by the parathyroid hormone (PTH). Disruptions in this balance due to non-physiological treatment conditions would, therefore, be reflected in the concentrations of Ca2+, phosphate, and PTH.



Pre- and post-treatment concentrations of phosphate with different treatment modes





As shown in Figures 26 and 27, however, no significant differences between online HDF post-treatment values with Citrasate and standard concentrate were observed.

Kron et al.²³ successfully performed a heparin-free online hemodiafiltration in pre-dilution mode with patients at risk of bleeding and HIT II using calcium-free Citrasate as dialysis fluid and substitution solution. 32 treatments were performed without clotting problems. To maintain a constant concentration of calcium ions in the plasma, it was necessary to infuse calcium chloride into the venous line.

Online hemodiafiltration in post-dilution mode

Following previous studies on the suitability of Citrasate concentrate for high-flux hemodialysis (HD) and online hemodiafiltration (HDF) in pre-dilution mode, it should now be investigated whether the use of citrate-containing dialysate can present issues during online HDF in post-dilution mode. In contrast to HDF pre-dilution, the infusion of citrate-containing solution with online HDF post-dilution occurs after the dialyzer (i.e. directly into the peripheral blood of the patient), so the physiological effects are more difficult to assess.

As with online HDF pre-dilution, the following questions were posed: Is it possible for online HDF postdilution ...

- ...to maintain the reduced heparin amount of 50%?
- ...to improve the dialysis efficacy?
- ...to reduce the activation of MPO?
- ...to keep plasma concentrations of calcium and phosphate in the physiological optimal range?

Seven out of the eight patients from the online HDF pre-dilution study continued with the post-dilution investigation, as one patient dropped out. The heparin dosage was reduced between 30-50% compared to the baseline in studies involving high-flux dialysis and acetate-containing standard concentrate.

The following treatment parameters were used:


- Dialyzer surface area: 2,2 m²
- Blood flow: 300 ml/min
- Dialysate flow: 500 ml/min
- Substitution rate for post-dilution: 60 ml/min.

THE RESULTS ARE SUMMARIZED IN THE SECTIONS THAT FOLLOW...

Reduction in heparin dose

In principle, Citrasate can be used for online HDF in post-dilution with a reduced amount of heparin (up to 50%) compared to standard dialysate.

Fig. 28 compares the activated prothrombin times (aPTT) in four different treatment modes using either Citrasate or standard concentrate. There is clearly no influence of Citrasate on the activation of systemic coagulation.






Fig. 28: aPTT pre- and post-treatment; n=7 Activated prothrombin times pre- and post-treatment with different treatment modes

Increase in dialysis efficacy and β2 Microglobulin removal

Online HDF post-dilution proved to be more effective than high-flux HD and online HDF predilution in the removal of low molecular weight molecules (e.g. urea).


However, a difference in effectiveness between online HDF post-treatment with Citrasate and standard concentrate could not be detected (see Fig. 29).

Regarding the removal of β 2 Microglobulin, an improvement in effectiveness compared to high-flux HD could be seen, but a difference between online HDF post-dilution with Citrasate and standard concentrate, as it was seen in the pre-dilution treatments, could not be determined.


The level of calcium and phosphate in plasma


As seen during the HDF pre-dilution treatments, the concentration of calcium was raised to 1.50 mmol/l for the online HDF post-dilution treatments.

Fig. 31 shows the Ca2+ concentrations level out to values of about 1.10 mmol/l after treatment, as seen with online HDF treatments using standard dialysate (Ca2+ = 1.25 mmol/l). Losses of ionized calcium by chelation were adequately compensated by choosing a higher dialysate Ca2+ for online HDF in both preand post-dilution. Fig. 32 demonstrates that the total calcium amount is reduced more significantly in online HDF post-dilution with standard concentrate than the same treatment with Citrasate.




different treatment modes with and without Citrasate





This can be explained by the metabolization of citrate during treatment, where chelated calcium will be released into the blood. As already described in the section on online HDF pre-dilution, changes in the balance between ionized and total calcium can be described by the Ca-GAP, which should be less than 0.2 (13, 29).

Fig. 33 shows that online HDF post-dilution with Citrasate gives better results than with standard concentrate for total Ca-GAP.




Accordingly, no surplus amount of bound Ca remains in the bloodstream, which would indicate an incomplete metabolism of the calcium citrate. According to studies by E. Bauer et al.²⁹, this is also not to be expected. In this study, citrate kinetics during citrate anticoagulation were investigated both in patients with normal renal function and those undergoing hemodialysis. It was found that citrate is also metabolized adequately with renal failure, as well as with mild hepatic dysfunction. Only in patients with severe liver failure is citrate anticoagulation not indicated. If one considers that, with citrate anticoagulation, the citrate infusion rate is about 0.3 mmol/kg/h, while with online HDF in

post-dilution with Citrasate dialysate, it is only about 0.04 mmol/kg/h, then problems arising from incomplete citrate metabolism are not to be expected.

As shown in Figures 34 and 35, however, no significant differences between online HDF post-dilution treatment values with Citrasate and standard concentrate were observed.

Regarding other parameters measured, such as bicarbonate (HCO₃⁻), Na⁺, K⁺, there were no significant differences in the individual study phases.



The mean EPO dose (Aranesp®) and iron intake (Ferrlecit) remained constant during all study phases.

Fig. 34: Phosphat pre- and post-treatment; n=7 Plasma phosphate concentrations pre- and post-treatment for different treatment modes with Citrasate and standard concentrate




Fig. 35: iPTH pre-treatment; n=7 Pre-treatment concentration of intact parathyroid hormone (iPTH) for different treatment modes with Citrasate and standard concentrate

Citrasate can be used on every standard dialysis machine

MACHINES AND METHODS

Polakovic et al.²⁵ carried out double measurements with A-concentrate with acetic acid (AA) or citric acid with seven types of dialysis machines from four manufacturers: Dialog by B.Braun, 4008/5008 by Fresenius, AK 100/200/200S by Gambro, and DBB05 by Nikkiso and Surdial X by Nipro.

All machines were preset for conventional acetate-containing A-concentrates.

- Concentrations of Na⁺-, K⁺-, Ca²⁺ in final dialysate were measured by ion selective electrodes. The bicarbonate concentration was calculated from measured pH and pCO₂ values.
- Measurements were performed for four different combinations of sodium and bicarbonate set values covering the whole range of commonly used settings (132/28, 132/39, 148/28, and 148/39 mmo/l).

Results of the in vitro measurements²⁵

- 1. The performance of all tested dialysis machine types was problem-free and without any alarms.
- 2. The control of Na+ und HCO3- concentration worked with the entire concentration range for all machines tested.
- **3.** The concentration of ionized calcium was found to be 0.35-0.55 mmol/l lower in the citrate-containing dialysate.
- **4.** The bicarbonate concentration exhibited a tendency towards slightly higher values (0.5-2.5 mmol/l) when using Citrasate concentrate compared to standard dialysate, depending on the type of mixing system (volumetric or conductivity) of the dialysis machine.



Advantages of using Citrasate

The following applies to treatments in high-flux HD and online HDF in either pre- or postdilution:

- The use of Citrasate allows for the reduction of heparin by up to 50% without the increased risk of clotting issues in the extracorporeal circuit or dialyzer, and without a reduction of dialysis dose prescribe
- The use of Citrasate keeps plasma concentrations of calcium and phosphate in a physiologically optimal range
- The use of Citrasate can reduce long bleeding times for patients with high risk of bleeding
- The use of Citrasate increases the hemodynamic stability of hypertensive patients during high-flux HD treatment
- The use of Citrasate was proven to be more biocompatible for chronic dialysis patients by decreasing inflammatory and oxidative stress
- The successful application of Citrasate works on every standard dialysis machine
- The level of ionized Ca with Citrasate corresponds to that of standard dialysate with 1.25 mmol/l Ca²⁺ after an increase of dialysate calcium from 1.25 to 1.50 mmol/l
- The use of Citrasate offers an economical benefit by helping hospitals save on heparin

Comparison of the composition of ready-to-use citric acid dialysis solution *versus* acetic acid

The electrolyte concentrations shown below are related to ready-to-use dialysis solutions in dilution/the following dilution ratio?:

1 L of Dxxx + 1,225 L of bicarbonate concentrate + 32,775 L of purified water

1 liter bicarbonate concentrate contains 84.0 g NaHCO₃

Туре		Na+	K+	Ca++	Mg++	Cl-	Citrate-	Acetate-	HCO3-	Glucose anh.
		mmol/l	mmol/l	mmol/l	mmol/l	mmol/l	mmol/l	mmol/l	mmol/l	g/l
Citrasate	416	135.30	1.00	1.25	0.50	104.50	0.80	0.30	32.60	1.00
Acetate	259	138.00	1.00	1.25	0.50	107.50		3.00	32.00	1.00
Citrasate	417	135.30	1.00	1.50	0.50	105.00	0.80	0.30	32.60	1.00
Acetate	296	138.00	1.00	1.50	0.50	108.00		3.00	32.00	1.00
Citrasate	410	135.30	2.00	1.25	0.50	105.50	0.80	0.30	32.60	1.00
Acetate	761	138.00	2.00	1.25	0.50	108.50		3.00	32.00	1.00
Citrasate	411	135.30	2.00	1.50	0.50	106.00	0.80	0.30	32.60	1.00
Acetate	293	138.00	2.00	1.50	0.50	109.00		3.00	32.00	1.00
Citrasate	412	135.30	3.00	1.25	0.50	106.50	0.80	0.30	32.60	1.00
Acetate	283	138.00	3.00	1.25	0.50	109.50		3.00	32.00	1.00
Citrasate	413	135.30	3.00	1.50	0.50	107.00	0.80	0.30	32.60	1.00
Acetate	257	138.00	3.00	1.50	0.50	110.00		3.00	32.00	1.00
Citrasate	414	135.30	4.00	1.25	0.50	107.50	0.80	0.30	32.60	1.00
Acetate	263	138.00	4.00	1.25	0.50	110.50		3.00	32.00	1.00
Citrasate	415	135.30	4.00	1.50	0.50	108.00	0.80	0.30	32.60	1.00
Acetate	787	138.00	4.00	1.50	0.50	111.00		3.00	32.00	1.00

Type D 200 dilution	Na+mmol/l	HCO₃⁻ mmol/l
1+1.225+32.775	35	35

The electrolyte concentrations shown below are related to the ready-to-use dialysis solution in dilution 1:45:

1 L of Dxxx + 1,775 L of bicarbonate concentrate + 42,225 L of purified water

1 liter bicarbonate concentrate contains 84.0 g NaHCO₃

Туре		Na+	K+	Ca++	Mg++	Cl-	Citrate-	Acetate-	HCO3-	Glucose anh.
		mmol/l	mmol/l	mmol/l	mmol/l	mmol/l	mmol/l	mmol/l	mmol/l	g/l
Citrasate	460	139.75	2.00	1.50	0.50	106.00	0.80	0.30	37.04	1.00
Acetate	871	139.00	2.00	1.50	0.50	106.00		3.00	36.00	1.00
Citrasate	463	139.75	3.00	1.50	0.50	107.00	0.80	0.30	37.04	1.00
Acetate	874	139.00	3.00	1.50	0.50	107.00		3.00	36.00	1.00

Dilution with bicarbonate concentrate	Na+mmol/l	HCO₃⁻ mmol/l
1+1.775+42.225	39.44	39.44

Other compositions are available upon request. For packaging sizes, please contact your local Nipro representative.

Please contact your country representative for product availability and information.

Literature

- 1. Vinay P. Acetate metabolism during dialysis: metabolic considerations. Am. J. Nephrol. 1987; 7:337-354
- 2. Bingel M et al. Enhancement of in vitro human Interleukin I production by sodium acetate. The Lancet 1987; 329:14-16
- **3.** Diamon S. et al. Comparison of acetate free citrate hemodialysis and bicarbonate hemodialysis regarding effects of intradialytic hypotension and malaise. Therapeutic Apheresis and Dialysis 2011;15: 460-465
- **4.** Elisaf MS et al. Effects of conventional and low molecular weight heparin on lipid profile in hemodialysis patients. Am J Nephrol 1997;17:153-157
- 5. Sela S. Oxidative stress during hemodialysis: Effect of heparin. Kidney Int 2001;59:159-163
- 6. Malle et al. Myeloperoxidase in kidney disease. Kidney Int 2003; 64:1956-1967
- 7. Sackler JP et al. Heparin-induced osteoporosis. Brit J of Radiology 1973;46:548-550
- 8. Asmis LM et al. Heparin-induzierte Thrombozytopenie (HIT). Schweiz. Med. Forum 2004; 4:997-1002
- **9.** Kossmann RJ et al. Fifty-five percent heparin reduction is safe with Citrasate dialysate in chronic dialysis Patients. ASN Renal week Meeting, 2006, Abstract No. 708
- **10.** Ahrenholz P et al. Heparin reduction and improved compatibility using citrate enriched dialysate. EDTA Congress , Paris 2012, Abstract and poster FP 434
- **11.** Kossmann RJ et al. Increased efficiency of hemodialysis with citrate dialysate, A prospective controlled study. CJASN 2009; 4:1459-1464
- **12.** Svara F et al. Long term use of A-Concentrate Citrasate during Bicarbonate dialysis. Kidney & Blood Pressure Research 2010; 33:318 (abstract)
- Gabutti L et al. Citrate vs. Acetate-based dialysate in bicarbonate haemodialysis: consequences on haemodynamics, coagulation, acid-base status and electrolytes. BMC Nephrology 2009; 10:471-2369/10/7
- **14.** Hofbauer R et al. Effect of anticoagulation on blood-membrane interaction during hemodialysis. Kidney Int 1999;56:1578-1583
- 15. Advanced Renal Technologies Inc. USA 2008, personal information
- **16.** Leimbach T et al. Heparin-Einsparung durch Verwendung von citrathaltigem Dialysat? Kongress für Nephrologie 2011, Berlin, Poster 36
- **17.** Hörl W Die Antikoagulation mit Zitrat reduziert die Mortalität und verbessert die Erholung der Nierenfunktion bei Patienten mit akutem Nierenversagen. Nephro-News 2008, Ausgabe 05/08
- Lau D et al. MPO mediates neutrophil activation by association with CD11b/CD18 Integrins. Proc. Natl Acad Sci USA 2005; 102:431-36
- **19.** Krieter DH et al. A new sythetic dialyzer with advanced permselectivity for enhanced low molecular weight protein removal. Artif Organs 2008; 32:547-554
- **20.** Gritters M et al. Citrate anticoagulation abolishes degranulation of polymorphonuclear cells and platelets and reduces oxidative stress during hemodialysis. Nephrol Dial Transplant 2006;21:153-159
- **21.** Oudemans-van Straaten HM et al. Citrate anticoagulation for continuous venovenous hemofiltration. Crit. Care Med 2009;37:545-552

- 22. Polakovic V et al. Bicarbonat hemodialysis and hemodialfiltration using citric-acid containing A-concentrate. 9th International Nephrological Symposium: Metabolic changes in chronic renal failure, Aktuality v Nefrologii 2010; 16:13 (abstract)
- **23.** Kron J et al. Regionale Antikoagulation durch Prädilutions Hämodiafiltration mit calciumfreien citrathaltigem Dialysat. Kongress für Nephrologie 2011, Berlin, Poster 29
- **24.** Ahmad S and Tu A Heparin Free Slow Efficience Dialysis (SLED) using Citrate dialysate: Is safe and effective. Blood Purif. 2007; 25: 191 (abstract)
- **25.** Polakovic V et al. Citrasate dialysis concentrate: In vitro tests and results of the citrasate use and in vivo bicarbonate haemodialysis and online haemodiafiltration, Prague V/2008- I/2010.
- **26.** Sands JJ et al. Effects of citrate acid (Citrasate) on Heparin N Requirements and hemodialysis Adequacy: A multicenter, prospective noninferiority trial. Blood. Purif. 2012;33:199-204
- 27. Ahrenholz P et al. Heparin-Reduzierung und verbesserte Hämokompatibilität durch Citrasate-Konzentrat bei High-Flux-Hämodialyse und Hämodiafiltration. Kongress für Nephrologie 2012, Hamburg, Abstract und Poster P115.
- **28.** Winkler RE et al. Reduction of Heparin and Oxidative Potential by means of Citrasate in High-Flux Dialysis (HFD) and Online Hemodiafiltration (olHDF) in Pre- and Postdilution. in "Hemodialysis" ed. by Hiromichi Suzuki, 2012, Verlag InTech Rijeka (im Druck)
- **29.** Bauer E et al. Citrate kinetics in patients receiving long-term hemodialysis therapy. Am J Kidney Dis. 2005; 46(5):903-7

Nipro Renal Care is part of Nipro Corporation Japan, a leading global healthcare company established in 1954. With over 33.000 employees worldwide, Nipro serves the Medical Device, Pharmaceutical, and Pharmaceutical Packaging industries.


Nipro Renal Care is a global market leader with over 5 decades providing renal solutions for dialysis and dialysis-related treatment. We specialize in developing dialysis machines, water treatment systems, and a comprehensive portfolio of disposable medical equipment.

In order to address the needs of patients, healthcare professionals, and procurement managers alike, Nipro Renal Care is driven by innovation and patient safety to offer the highest quality products that optimize time, effort, and costs.

BECAUSE EVERY LIFE DESERVES AFFORDABLE CARE



www.nipro-group.com/en-en/our-company/our-locations





Nipro Medical Europe : European Headquarters, Blokhuisstraat 42, 2800 Mechelen, Belgium T: +32 (0)15 263 500 | F: +32 (0)15 263 510 | medical@nipro-group.com | www.nipro-group.com